GTS Securities’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-49,000
Closed -$5.64M 3157
2024
Q3
$5.64M Buy
49,000
+17,100
+54% +$1.94M 0.01% 818
2024
Q2
$3.4M Buy
31,900
+7,800
+32% +$783K 0.01% 1116
2024
Q1
$2.33M Sell
24,100
-49,700
-67% -$5.1M ﹤0.01% 1379
2023
Q4
$7.45M Sell
73,800
-28,200
-28% -$2.72M 0.01% 763
2023
Q3
$10.4M Buy
+102,000
New +$10.4M 0.02% 584

Other funds holding NVS

GTS Securities's NVS Position: Q1 2026 in Review

GTS Securities sold out of Novartis (NVS) in Q1 2026, closing a stake of 2,018 shares — an estimated $278K sold.

GTS Securities first reported a position in NVS in Q3 2024 and held it in 6 quarters. The position peaked at $1.6M in Q3 2025. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • GTS Securities reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
  • GTS Securities sold 2,018 Novartis shares in Q1 2026, an estimated $278K.
  • GTS Securities first reported a position in Novartis in Q3 2024 and held it in 6 quarters.
  • GTS Securities's Novartis position peaked at $1.6M in Q3 2025.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.